Top Markets
#1 Nesa Nesa +720.45%
#2 EXOD EXOD +22.78%
#3 MetaDAO MetaDAO +14.20%
#4 Venom Venom +10.59%
#5 Pons Pons +9.49%
#6 PondCoin PondCoin +8.69%
#7 Status Status +8.08%
#8 Wrapped NXM Wrapped NXM +8.03%
#9 Prom Prom +7.99%
#10 Ontology Gas Ontology Gas +7.17%
Coin of the day
Nesa Nesa
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Connect Biopharma Holdings Limited Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

CNTB
Rangering i aksjer #19727
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical... Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Aksjekurs
$2.42
Sist synkronisert: 2026-08-25
Markedsverdi
$152.37M
Endring (1 dag)
5.22%
Endring (1 år)
39.88%
Land
US
Handel Connect Biopharma Holdings Limited (CNTB)

Kategori

Healthcare
Antall utestående aksjer for Connect Biopharma Holdings Limited (CNTB)
Antall utestående aksjer per August 2026: 0
Ifølge Connect Biopharma Holdings Limited sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av August 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Connect Biopharma Holdings Limited (CNTB) fra 2026 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
Ikke nok data for de angitte datoene.
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH